Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety Vs. hydroxyethyl cellulose-based universal placebo gel

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 161-169

  Nel, Annalene M ^a   Smythe, Shanique C ^a   Habibi, Sepideh ^a   Kaptur, Paulina E ^a   Romano, Joseph W ^a,b  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b NONE   (United States)

Author keywords

Dapivirine; HIV prevention; Microbicide; Pharmacokinetics; Vaginal gel

Indexed keywords

DAPIVIRINE; HYDROXYETHYLCELLULOSE; PLACEBO; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TMC120-R147681;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; EOSINOPHIL; ERYTHEMA; FEMALE; GEL; GENITAL HERPES; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTE; LOWER ABDOMINAL PAIN; LYMPHOCYTE; MALAISE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; NEUTROPHIL; NORMAL HUMAN; PELVIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE; STOMACH DISCOMFORT; THROMBOCYTE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; VOMITING; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; CHEMICALLY INDUCED; VAGINA DISEASE;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HEMORRHAGE; HIV REVERSE TRANSCRIPTASE; HUMANS; PYRIMIDINES; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL DISEASES;

EID: 77957323094     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e3293a     Document Type: Article

References (24)

1. Report on the global HIV/AIDS epidemic 2008: executive summary. July 2008. UNAIDS/08.27E/JC1511E. Available at: http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp. Accessed August 1, 2009.
2. Nel AM, Coplan P, van de Wijgert JH, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy HIVnegative women. AIDS. 2009;23:1531-1538.
3. Trottier S, Omar RE, Désormeaux A, et al. Safety, tolerance and acceptability of the Invisible Condom- and its vaginal applicator in healthy women and their male sexual partners. Contraception. 2007;76: 117-125.
4. Jespers VA, Van Roey JM, Beets GI, et al. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIVpositive female volunteers. J Acquir Immune Defic Syndr. 2007;44: 154-158.
5. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr. 2006; 43:327-334.
6. Malonza IM, Mirembe F, Nakabiito C, et al. Expanded phase 1 safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS. 2005;19: 2157-2163.
7. Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94:1159-1164.
8. Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Womens Health (Larchmt). 2003;12:655-666.
9. Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53:487-495.
10. Nuttall JP, Thake DC, Lewis MG, et al. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother. 2008;52:909-914.
11. Romano J, Malcolm RK, Garg S, et al. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS. 2008;3:558-566.
12. Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006;325:82-89.
13. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56:954-956.
14. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120- R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004;48:337-339.
15. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS. 2003;17: 1597-1604.
16. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51: 416-423.
17. Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25:483-488.
18. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception. 2007;75: 136-141.
19. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005;21:845-853.
20. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS- AE-GradingTable-FinalDec2004.pdf. Accessed August 1, 2009
21. Van't Klooster G, Van Der Geest R, Gillé D. A Phase IIa Randomized, Double-Blind, Placebo-Controlled, Single Drug Therapy, Dose-Finding Trial in 36 Antiretroviral Naïve, HIV-1 Positive Subjects Receiving Either Placebo, 50 or 100 mg of TMC120 (R147681) b.i.d. During a 7-Day Treatment Period. Tibotec Pharmaceuticals Ltd.; 2005. Clinical Research Report No. TMC120-105-CRR.
22. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
23. Vingerhoets J, de Béthune MP. Summary of the Primary Pharmacology (Virology) Data for TMC120 up to June 2005. Tibotec Pharmaceuticals Ltd.; 2005. Study Report No. TMC120-20040005-VSUM.
24. Van't Klooster G, Woodfall B, Gillé D, et al. Randomized, Placebo- Controlled, Double-Blind, Dose Escalating Trial to Examine the Safety, Tolerability and Pharmacokinetics of Oral Twice-Daily TMC120 Doses in Healthy Subjects. Tibotec Pharmaceuticals Ltd.; 2003. Clinical Research Report No. TMC120-C123.